

130 E Aurora Ave
Des Moines, IA 50313-3654
February 26, 2017

Jarad Klein
1744 Keokuk Washington Rd.
Keota, IA 52248

Dear Rep. Klein,

I am writing regarding HSB 164, an Act relating to the medical use of cannabidiol including the rescheduling of a cannabidiol investigational product approved as a prescription drug medication under federal law.

I believe it is unnecessary to instruct the Iowa Board of Pharmacy to schedule a product before it is known whether the product will be approved by the FDA and the DEA, and before it is known what schedule, if any, that product might be placed in by the FDA and the DEA.

I have asked the Iowa Board of Pharmacy to review SF 282, HSB 159, and HSB 164, at their next meeting on Wednesday, March 8, 2017. I am attaching my letters to the Iowa Board of Pharmacy for your review.

Please amend the bill by striking the language about federal scheduling.

Thank you!

Sincerely,

Carl Olsen
515-343-9933
carl-olsen@mchsi.com